- About Us
- Our Work
- Work With MSF
- Public Events
- Press Room
Joint Press Release: Doctors Without Borders/Médecins Sans Frontières (MSF), Treatment Action Campaign (TAC), and Oxfam
Importation of Generics Cuts Price in Half
Johannesburg, January 29, 2002 — Yesterday, three members of the Treatment Action Campaign, (TAC) returned to South Africa from Brazil carrying generic drugs manufactured for use in an AIDS treatment program in Khayelitsha. At a press conference today, TAC and Doctors Without Borders/ Médecins Sans Frontières (MSF) explained that the drugs carried from Brazil were the second shipment of Brazilian drugs and that as of today 50 people are already taking the Brazilian medicines in Khayelitsha.
To guarantee the quality of these drugs, an authorization from the Medicines Control Council (MCC), the South African drug regulatory authority, was obtained prior to their use.
"Last week in Brazil we saw what happens when a government decides to tackle HIV/AIDS. The Brazilians' decision to offer universal access to antiretroviral therapy even in the poorest areas of the country is keeping tens of thousands of people alive," said Zackie Achmat of the Treatment Action Campaign. "Central to the success of Brazil's AIDS program is their willingness to do anything necessary to source the lowest cost quality antiretrovirals. The South African government should pursue compulsory licensing to ensure that generic antiretrovirals can be produced and/or imported in South Africa."
At a press conference today, the non-governmental organizations said that the court victory of the South African government against multinational pharmaceutical companies had opened the door to improved access to affordable medicines. "The South African government may need international financial help to provide treatment, but these needs will be dramatically reduced if the government takes steps to use the most affordable drugs available on the worldwide market, as the multinational pharmaceutical companies are still charging high prices for these drugs," said Dan Mullins of Oxfam.
Despite the national government's refusal to provide antiretroviral treatment, three clinics run by MSF within the government primary health care centers offer a comprehensive package of services to people living with HIV/AIDS, including antiretroviral therapy. This project is part of an agreement between MSF and the government of the Western Cape, signed two years ago with the express intent to test the feasibility of antiretroviral therapy. These clinics, located in Khayelitsha, a sprawling township of 500,000 people outside Cape Town, were opened in April 2000 and have provided treatment for opportunistic infections for over 2,300 people living with HIV/AIDS.
In May 2001, combination antiretroviral therapy was introduced for a group of people in advanced stages of AIDS. To date, 85 people have received antiretroviral therapy and 50 of these are receiving Brazilian medicines. Using generic antiretrovirals offers the possibility of treating twice the number of people with the same amount of money.
"I have personally benefited from the MSF antiretroviral program, and I have gone to Brazil to bring back generics so that more people like me can have access to these medicines," said Matthew Damane, a person living with AIDS who is receiving antiretroviral therapy as part of the MSF program in Khayelitsha. "The government should publicly accept the effectiveness of these medicines and make them available to people with AIDS in South Africa."
"Our project shows that antiretroviral therapy is feasible in a resource-poor setting, contrary to those who insist that poor Africans are not able to successfully take these drugs. Patients who were critically ill are now returning to their normal lives," said Dr. Eric Goemaere of MSF South Africa. "We have seen firsthand that these drugs can be used safely and effectively here in South Africa. As medical professionals, it is our duty to offer these benefits to as many patients as possible."
Similar initiatives are springing up elsewhere around the country as medical staff become increasingly frustrated by the lack of action from the national government. Nonetheless, the price of medicines continues to be a critical problem.
MSF has signed agreements with the Brazilian Ministry of Health (MoH) and Fiocruz, a public research body funded by the Brazilian government. The former established a cooperative agreement involving technical collaboration on the response to HIV/AIDS, so that MSF and the Brazilian MoH can collaborate to improve the delivery of treatment in resource-poor settings. The agreement with Fiocruz allows MSF to purchase antiretroviral drugs produced by FarManguinhos, the Brazilian national pharmaceutical producer, which is part of Fiocruz.
An innovative aspect of this arrangement is that the money MSF pays for these drugs will go directly into research and development for AIDS and neglected diseases such as sleeping sickness, Chagas disease, and malaria (all diseases for which current treatment options are inadequate).
MSF is currently using the antiretroviral drugs AZT, 3TC, co-formulated AZT/3TC, and nevirapine produced by FarManguinhos. By using these drugs the price per patient per day falls from US$3.20 to US$1.55.
In 1996, in response to pressure from civil society, the Brazilian government began providing free access to antiretroviral therapy to people with HIV/AIDS. This policy has allowed more than 100,000 people to receive antiretroviral therapy and reduced AIDS-related mortality by more than 50%. Between 1997 and 2000, antiretroviral treatment has saved the Brazilian government $677 million on hospitalizations averted and treatment for opportunistic infections averted.
South Africa could launch a similar program. To do so, the government needs to have access to the lowest cost medicines, whether they come from multinational pharmaceutical companies or from generic producers. This means both taking advantage of offers from multinational companies and being willing to seek compulsory licenses. These licenses can be used to produce these drugs locally or import them and are an important way to stimulate competition, which is a powerful tool to reduce prices.